Bio Pharma Dive
MARCH 24, 2022
At least nine biotechs working in cell or gene therapy have announced layoffs, cost cuts or restructured their research since December — restructurings that have coincided with a stock market downturn.
World of DTC Marketing
MARCH 5, 2022
American healthcare is the most expensive globally, but it’s not close to being the best. Our healthcare system has become like a mass-market retailer, in the door to treat the problem and out the door with an Rx or other treatment recommendation. What’s missing is the basic premise of any good care: the focus on the person, not just the condition.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 17, 2022
The uptake of digital health tools during the pandemic has been enormous due to improved access they provide to healthcare. In this article, Ben Hargreaves asks whether there are gaps in those utilising these solutions and what action is being taken to address this. Digital health has a tremendous capacity to transform the healthcare industry, with the ability to provide easy access to a multitude of services and new types of therapies.
BioPharma Reporter
MARCH 24, 2022
Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Scienmag
MARCH 18, 2022
Artificial intelligence advances how scientists explore materials. Researchers from Ames Laboratory and Texas A&M University trained a machine-learning (ML) model to assess the stability of rare-earth compounds. This work was supported by Laboratory Directed Research and Development Program (LDRD) program at Ames Laboratory. The framework they developed builds on current state-of-the-art methods for experimenting with […].
Pharma Times
MARCH 24, 2022
The platform to build a digital-ready frontline workforce will be available to all NHS and social care staff
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
World of DTC Marketing
MARCH 27, 2022
Mental illnesses are common in the United States. Nearly one in five U.S. adults live with a mental illness (52.9 million in 2020). Mental illnesses include many different conditions that vary in severity, ranging from mild to moderate to severe. Suicidal ideation continues to increase among adults in the U.S. 4.58% of adults report having serious thoughts of suicide, an increase of 664,000 people from last year’s dataset.
pharmaphorum
MARCH 13, 2022
The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown. The new approval is for use in patients with BRCA-mutated, HER2-negative early-stage breast cancer who have already been treated with chemotherapy – either before or after surgery – and are at high risk of the disease coming back.
Drug Patent Watch
MARCH 22, 2022
FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…. The post DrugPatentWatch Week in Review appeared first on DrugPatentWatch - Make Better Decisions.
XTalks
MARCH 23, 2022
“Cholesterol-free,” “low-fat,” “super light,” “sugar-free” or “anti-ageing” are all examples of believable claims on food labels. However, only two of these claims are legally permitted in the European Union. Since consumers are more health-conscious than ever, some food manufacturers are pulling out all the stops to convince people to purchase highly processed and unhealthy products with misleading food labeling. .
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
MARCH 21, 2022
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery
Bio Pharma Dive
MARCH 23, 2022
The deal, announced alongside a $175 million round, makes biotech entrepreneur Greg Verdine's startup the most well-funded among an emerging group of companies searching for drugs in fungal DNA.
World of DTC Marketing
MARCH 28, 2022
Oxford researchers say they have confirmed that alcohol is a direct cause of cancer, emphasizing how their findings reinforce the need to lower levels of alcohol consumption in the population for cancer prevention. The question is will the healthcare community do anything about these findings? Worldwide, alcohol is responsible for an estimated 3 million deaths each year, with over 400,000 from cancer.
pharmaphorum
MARCH 7, 2022
A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including the Boehringer Ingelheim Venture Fund. The Princeton, New Jersey-based startup will use the funding to develop its artificial intelligence and imaging based drug discovery platform, used to identify compounds with new and under-exploited mechanisms of action.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
MARCH 22, 2022
Drugs contain ingredients with therapeutic activity, so-called “active ingredients” as well as inactive ingredients. These inactive ingredients, called excipients, are included in oral products for various reasons, such as to…. The post 2 Strategies to Grow Your Excipient Business by Tracking Drug Patents appeared first on DrugPatentWatch - Make Better Decisions.
BioPharma Reporter
MARCH 14, 2022
The first participant has been dosed in a Phase 1 clinical trial of HIV trimer mRNA vaccine candidate mRNA-1574.
Pharma Times
MARCH 30, 2022
Report uses input from healthcare professionals to highlight training and support needs, while also warning about departures
Bio Pharma Dive
MARCH 15, 2022
Stung by a stock market downturn, a number of biotechs are trimming spending and reprioritizing research to save cash. Passage's layoffs will reduce its workforce by 13%.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
World of DTC Marketing
MARCH 6, 2022
Digital health companies aim to address the numerous health care challenges, including poor patient engagement, communication gaps between patients and providers, lack of longitudinal data, inconvenience of care delivery, and insufficient clinical decision support for providers and patients. Maybe, however, they should check with patients first. A 2016 study reported that 259,000 digital health apps were available for consumers.
pharmaphorum
MARCH 22, 2022
Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there is particular potential for the technologies to revolutionise staff training and reduce costs in pharma manufacturing. Virtual reality (VR) and augmented reality (AR) have spent a lot of time in the headlines recently.
Outsourcing Pharma
MARCH 14, 2022
The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.
BioPharma Reporter
MARCH 15, 2022
Sanofi and Blackstone today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to â300m ($329m) to accelerate development for subcutaneous formulation and delivery of anti-CD38 antibody Sarclisa to treat patients with multiple myeloma (MM).
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
Pharma Times
MARCH 15, 2022
COVID-19 has highlighted another significant widespread problem – the mental health pandemic
Bio Pharma Dive
MARCH 1, 2022
Biotech CEOs Paul Hastings and Jeremy Levin explained the goals behind a letter supported by more than 400 executives and investors that calls for drugmakers to stop working with Russian companies.
World of DTC Marketing
MARCH 31, 2022
The House is preparing to vote on a $35 monthly insulin cap later, but there is stern opposition to the plan, which could cost billions over ten years. Essentially taxpayers would be subsidizing drug company profits for the price of a product that should have come down a long time ago. Under the bill proposed, Medicare beneficiaries and those insured through private plans would pay no more than $35 for a 30-day insulin prescription, or the lesser of $35 or 25% of the plan’s negotiated pric
pharmaphorum
MARCH 2, 2022
Amazon’s encroachment into healthcare advanced a little further this week when the online giant launched a doctor consultation service delivered via its Alexa voice assistant, with the help of telehealth player Teladoc. Users of the service will be able to request non-urgent medical care around the clock, simply by telling Alexa via their Amazon Echo device that they want to speak to a doctor.
Speaker: Steve Goldstein, Sales Leader
Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? What are some of the top challenges your customers face and how do you approach understanding what’s most important to them? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., to discover critical strategies and approaches you can take to engage your customers, achieve g
Scienmag
MARCH 21, 2022
Deaths from cancer are expected to increase over the next decade as a result of screening deficits due to the COVID-19 pandemic. New research published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, reveals the extent of screening deficits in breast, colorectal, lung, and cervical cancers across the United States […].
BioPharma Reporter
MARCH 3, 2022
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies to market more quickly.
Pharma Times
MARCH 17, 2022
The sub-variant combines mutations from both Omicron and Delta
Bio Pharma Dive
MARCH 16, 2022
Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
361 
Let's personalize your content